-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PvAasaSnPCc1Y9XQ83i/KyG4+guduPKExWV9tpFqRLosklgcUdYxzRM9uXvI9L4o
 1yenynQCqBtQ2ehqi5PHfw==

<SEC-DOCUMENT>0001144204-07-057366.txt : 20071031
<SEC-HEADER>0001144204-07-057366.hdr.sgml : 20071030
<ACCEPTANCE-DATETIME>20071031161516
ACCESSION NUMBER:		0001144204-07-057366
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071031
FILED AS OF DATE:		20071031
DATE AS OF CHANGE:		20071031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		071203022

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v091922_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: VF-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      October 31, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font>&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
      </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt"><font style="FONT-FAMILY: Wingdings" size="2">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt=""><br></div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated October 31,
      2007 is hereby incorporated by reference into the registration statements on
      Form F-3 (File No. 333-141529 and File No. 333-147024) filed by XTL
      Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March
      23,
      2007 and October 30, 2007, respectively.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Announces Delisting from the Official List of the United Kingdom Listing
      Authority</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Processing
      Fees on Transfer of Ordinary Shares into ADRs to be Waived for An Additional
      Month</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, October 31, 2007 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that the
      Company's ordinary shares have been delisted from the Official List of the
      United Kingdom Listing Authority, pursuant to the October 2, 2007 vote at the
      Company&#8217;s Extraordinary General Meeting. With the cancellation of the listing on
      the London Stock Exchange, shareholders may deposit their ordinary shares with
      the Company&#8217;s depositary bank, The Bank of New York, in exchange for American
      Depositary Receipts, or ADRs, which are traded on NASDAQ, or trade their
      ordinary shares on the TASE.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. has further announced that issuances of ADRs by The
      Bank
      of New York will be processed free of the customary charges of The Bank of
      New
      York for an additional month, through November 30, 2007. The Bank of New York
      will issue ADRs representing American Depositary Shares, or ADSs, if
      shareholders or their broker deposit Ordinary Shares with The Bank of New York&#8217;s
      Custodian, either the Tel Aviv office of Bank Hapoalim B.M., or the London
      office of The Bank of New York. One ADR will represent an ownership interest
      in
      ten of the Company&#8217;s Ordinary Shares. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interested
      investors should contact their brokers to discuss the waived fee and, should
      they have any questions, can contact The Bank of New York in either London
      or
      New York as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="65%">

          <tr>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">London</font></div>
            </td>
            <td align="left" valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>or</em></font></div>
            </td>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New
                York</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Lewis</font></div>
            </td>
            <td align="left" valign="top" width="10%">&#160;</td>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jason
                Paltrowitz</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
                President</font></div>
            </td>
            <td align="left" valign="top" width="10%">&#160;</td>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
                President</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel
                020.7964.6089</font></div>
            </td>
            <td align="left" valign="top" width="10%">&#160;</td>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel
                212.815.2077</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fax
                020.7964.6024</font></div>
            </td>
            <td align="left" valign="top" width="10%">&#160;</td>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fax
                212.815.3004</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="45%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>marlewis@bankofny.com</u></font></div>
            </td>
            <td align="left" valign="top" width="10%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="top" width="45%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">jpaltrowitz@bankofny.com</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="45%">&#160;</td>
            <td align="left" valign="top" width="10%">&#160;</td>
            <td align="left" valign="top" width="45%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of neuropathic pain and hepatitis C. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
      hepatitis C small molecule inhibitors. XTL also has an active in-licensing
      and
      acquisition program designed to identify and acquire additional drug candidates.
      XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:
      XTLB;
      TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating continued undisrupted trading of the Company&#8217;s ADRs on NASDAQ and
      similar matters, may be forward-looking statements that involve a number of
      risks and uncertainties. For those statements, we claim the protection of the
      safe harbor for forward-looking statements contained in the Private Securities
      Litigation Reform Act of 1995. Risk factors that could adversely affect our
      operations are identified from time to time in our reports filed with the
      Securities and Exchange Commission, including our annual report on Form 20-F
      filed with the Securities and Exchange Commission on March 23, 2007. Any
      forward-looking statements set forth in this press release speak only as of
      the
      date of this press release. We do not intend to update any of these
      forward-looking statements to reflect events or circumstances that occur after
      the date hereof. This press release and prior releases are available at
      http://www.xtlbio.com. The information in our website is not incorporated by
      reference into this press release and is included as an inactive textual
      reference only. This press release is for informational purposes only and is
      not
      an offer to by or the solicitation of an offer to sell any
      securities.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><strong><font size="2">XTL BIOPHARMACEUTICALS
              LTD.</font></strong></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              October 31, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive Officer </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0V'17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-SHQ,#HR
M-2`Q,3HR,CHR-P```````Z`!``,````!``$``*`"``0````!````JZ`#``0`
M```!````20`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```Q1````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`1`"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]55?J&;1T_!R,[()%.+6ZZR-3M8"]VW^
M5HN?^OV#UFWI)S^C9>1CY6#NLLIH>YHMJ_PK=C?I75;?4I_ZY7_A%YMTKZW=
M1;EM;UC-OSNDY3'8^=3:]SAZ%PV675_NVT_SOL]_^#4N/"9QX@=MX_I,<\@B
M0"-]B[#?\;?76YOVBW$Q_L$R[%;N]4,_DY&[:ZYK?^!]->J8V15E8U652=U5
M[&V5GQ:\;V_]$KS(_P"*>QESK<CJM7[&8/4?>&GUC2!O=W^SM_1_]J/^N^DN
M?ZK]<NKY&;;;TW,R,'IS`*L+%I>YC6TUCTZ?9_I;&C>]2RQ0R5[="AJL$Y0!
M]S6SH^Y)+SKJ-7UBZ)_B^NS<WJ.4>K9-E-CW&QQ=2USV-;C5_N?H_P"?_P"$
M7$_\Z/K/_P"6N;_VX],CRYE9$AH:7RRB-6#J^]I+P3_G1]9__+;,_P"W7)O^
M='UG_P#+7-_[<>G?=)?O!9]XCV+[XDO`_P#G1]9__+;,'QM</RKMO\5O5^K=
M0ZAU!F?FWY;*ZJRQMSR\-)<_<6[DV?+RC$R)!I=',)2X:+Z,DD@9SG-PLAS"
M6N;4\M<.00TZA0@6:9":!/9.DN4^HN=FY?VW[5D67[!5L]1Q=$BS=MW?O0NK
M3LN,XYF!-U6WBQ\OF&;%'(`0)7H?ZIX5))+E_K75]8;,RH]).0*A4=_HOVMW
M;N_N;[]J6.''(1XA'QELG-E]N!D(RG_5A\SU"2BV=HGF!*DF,BDDDDE/_]#U
M5>+?7WZL_L'K!?CLCIV>768\<,?S?B_CZM/_``7_`!2]I7+?XR+.E-^JU[.H
M`N>]S1@M;&_[3J:7,G\UGO\`7_[K^JI<$S&8K7BT(8\L1*)OIJ^=7?7#-M^I
M]7U;)=N99LLO_>Q&^ZG&F=V_?^B=_P!UJUI?XMOJN>J=2_:^6R<'I[_T33Q9
MD#5O_6\3^<_X_P!/_1V+C"'%I`,.C0^!7N/U'S>F9?U9P_V97Z%-#?1LQYDU
MVMUO8]WY[G/=ZWJ?X7U?55C.>"!X17$=2PX?7*Y&^$:!WDDDE2;3X+];/_%3
MU?\`\-/_`"-7K_U),_5+I/\`X5K_`.I7D'UL_P#%3U?_`,-/_(U>O_4G_P`2
M/2?_``K7^16N8_FX?RZ,&'YY_1Y?_'!_1.E_\=;_`-0U4?\`%!_RGU/_`(FK
M_JK%>_QP?T3I?_'6_P#4-5'_`!0?\I]3_P")J_ZJQ(?[F/\`+])!_G_H^HJO
MU#^@9/\`Q3_^I*L*OU#^@9/_`!3_`/J2JT?F'FS3^67D7@_JUUNCHV)FW/'J
M76^DVBD&-Q`LW.<[\UC-ROO^LGUO:#DNP=M$;M:+-H'B7;MZJ_4?!KR>INOM
M`<W$K#V`_P"D>=K'?V&ML7?J]S.3'#*?U8G(UQ&7E\L7,Y'%FR<O&LIQ1CQ"
M`@-_5K*;A_5_ZT4=7)HM:*,MHW!@,M>WNZEW\G\^M!^LWUER^C9-5-%-=K;:
MR\EY(((.W\U8/7JF]'^L[,C&'IL+J\AK1H!N)9<W^J_:_P#ST?Z__P!.Q?\`
MB7?]4E'!C.;&0/U>6)EPG]$@;*GS6:/+YHF59L$XP,Q^E&1TD]ID9-.+COR,
MEXKJJ&Y[SP`N2M^N/5<W(=3T;"W`:RYI>^/WWL86UT_VW*?U^S'MKQ<)I]C]
MUU@\=D-J'^<YSEN_5_IM73NETU-`]1[19>_NY[A+I_J_0:H81ACQ#)./'*9]
M$3\H$>K8R3RYN8EAQS]N&(`Y)Q^>4I;1B\\WZW==P+FLZOA#8[B&FMQ_XMSB
M^JS;^XNKP<[&S\5F5BOWU6#0]P1])CA^:]JCU/I]'4L*S$O$M>/:[NUP^A8W
M^4QRY+ZAY=E>=DX#S[7L]2.P?614_P#SVN_Z")CCRXI3C'@GCKB`^642B,\N
M#/#%DF<N/-8A*7SPG']%_]'U-[V,8Y[W!K&@ESB8``Y<XKP_ZY_69WUAZN_(
M8XCI^+NKPFGC;_A<DC]_(V_]L^FO0/\`&-D]=NP6]&Z/@Y&0W+$YF12PEHJF
M/LS7_P"DO=_._P#`?\:N1^I_U&ZGE];J=U?!MQ<#%BZP7-VBUS3^AQVS])N_
MWW?\%7Z?^$5G`(P!R2(OH&'+Q2(A'KN5LKZAY6/]2Z^MECOV@#]IR*-9;B.&
MC-G^FI;^LV?]=K_,53ZC?6;_`)O]8!O?'3<W;7E^#3_@,O\`ZU.VW_@/^+7M
M;FM<TM<`YKA!!U!![+QCZQ_47K'3^KWT=-P;\OI[SZF,^INX-8__`+3OU^E2
M[V?\7L3L>49!*&3KJ%L\9@8R@-M"^S@@B1J$ZY/_`!>Y?6QTP]+ZSAY&/;@@
M-Q[[F$"RD_S=>_\`TN/_`#?_`!7I+K%5E'A)&],X-BWP7ZV?^*GJ_P#X:?\`
MD:O7_J3_`.)'I/\`X5K_`"+S+ZS?5OZQ9'UCZI?C],R;:;<E[J[&5DM<T@0Y
MI_.7J/U1Q[\7ZL=,Q\FMU-]6.QME;Q#FN`U:YJLYR#CA1_E3#B!$YWU>3_QP
M?T3I?_'6_P#4-5'_`!0?\I=3_P")J_ZJQ:_^-/I?4^HXW3F]/Q+<MU=MAL%+
M=VT%K0W<O/C]5/K0?^\C+_[;/]Z=C$98>$R$;_BMGQ#+Q`7H^]2$#/UP<G_B
MG_\`4E>&?\T_K/\`^5&9_F'_`,DI5_5/ZSBVLGI.6`'M).P\`CS31R\00?<'
M\O\`"3++(@C@.SZ'_B^M8W(S*B?>^NM[1WAI>U__`)\8NV7GN!T/K]/J=0Q:
MK*,K%>"RI[8-C'#W^GN_G/W7U?G_`/&*\_ZV?61[30SIVS(.FX5V$@^+:G?]
M^>I.8P^[E,L<HG;BU^5I\ES/LX(PS0G`ZF'I,N,$_P#2:WUM/VSZRU8M6KVM
MII/]9[B__J;&HG^,#^G8W_$N_P"J5WZL_5S,;EGJW501=)=54\R_>[Z5]W\K
M_1L0OKMT[J&7FX[L3&LO:VIP<ZML@'=PGPG`9L4!($8HD&7Z/$1JQY<60\OG
MRF)$L\XRC#]*,(GT\2+_`!@4.]?$O'T7UOK^;2'_`/?EUO3<EF7T_'R*S+;*
MVNT\8]S?[+D+J_2J>K8+\2TEA,.JL`DL>/H/`_ZK^0N2Q;OK-]67.QSC?:,8
MDD`!SZY_?IMK]]6__1V,4,0,V&,`0,F,FA(UQQEV;,B>6YF>4Q,L.8"Y1'%[
M<X?O/<6VUTU/NL.VNMI<]Q[!HW.*X?ZCM?=UJ_)`A@J>YWQL>','_13YF=]9
M_K"T8=>&ZC'<?>`',:Z/]-?=M]G_``;%T_0.BU='P_2#O4OL.^^V(ET?1;_P
M;/S$J&##.,B#DR4.$&^&/]9%GF>8Q3C$C%AN7'(</',_HQ?_TO54DDDE*222
M24I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE/_]/U5)?*J22G
MZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?JI)?*J22G_]G_[1)"4&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))30/M```````0`$@````!``$`2```
M``$``3A"24T$)@``````#@`````````````_@```.$))300-```````$````
M>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*
M```````!```X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F
M9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&
M```````!`#4````!`"T````&```````!.$))30/X``````!P``#_________
M____________________`^@`````_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@``#A"24T$`````````@`!.$))300"```````$`````#A"
M24T$"```````$`````$```)````"0``````X0DE-!!X```````0`````.$))
M300:``````-)````!@``````````````20```*L````*`%4`;@!T`&D`=`!L
M`&4`9``M`#$````!``````````````````````````$``````````````*L`
M``!)``````````````````````$`````````````````````````$`````$`
M``````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``!)`````%)G:'1L;VYG````JP````9S;&EC97-6;$QS`````4]B:F,````!
M```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$
M;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T
M;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R``
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG````20````!29VAT;&]N
M9P```*L````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-
M<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT
M27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG
M;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L
M:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O
M;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET
M;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T
M=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-
M!"@```````P````!/_`````````X0DE-!!0```````0````".$))300,````
M``QM`````0```*````!$```!X```?X````Q1`!@``?_8_^``$$I&248``0(!
M`$@`2```_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1
M#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!$`*`#
M`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<(
M"0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(
M!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U
M`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086
MHK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U55^H9M'3\'(S
ML@D4XM;KK(U.U@+W;?Y6BY_Z_8/6;>DG/Z-EY&/E8.ZRRFA[FBVK_"MV-^E=
M5M]2G_KE?^$7FW2OK=U%N6UO6,V_.Z3E,=CYU-KW.'H7#99=7^[;3_.^SW_X
M-2X\)G'B!VWC^DQSR")`(WV+L-_QM]=;F_:+<3'^P3+L5N[U0S^3D;MKKFM_
MX'TUZIC9%65C595)W57L;96?%KQO;_T2O,C_`(I[&7.MR.JU?L9@]1]X:?6-
M(&]W?[.W]'_VH_Z[Z2Y_JOURZOD9MMO3<S(P>G,`JPL6E[F-;36/3I]G^EL:
M-[U++%#)7MT*&JP3E`'W-;.C[DDO.NHU?6+HG^+Z[-S>HY1ZMDV4V/<;'%U+
M7/8UN-7^Y^C_`)__`(1<3_SH^L__`):YO_;CTR/+F5D2&AI?+*(U8.K[VDO!
M/^='UG_\MLS_`+=<F_YT?6?_`,M<W_MQZ=]TE^\%GWB/8OOB2\#_`.='UG_\
MMLP?&UP_*NV_Q6]7ZMU#J'4&9^;?ELKJK+&W/+PTES]Q;N39\O*,3(D&ET<P
ME+AHOHR22!G.<W"R',):YM3RUPY!#3J%"!9ID)H$]DZ2Y3ZBYV;E_;?M619?
ML%6SU'%T2+-VW=^]"ZM.RXSCF8$W5;>+'R^89L4<@!`E>A_JGA4DDN7^M=7U
MALS*CTDY`J%1W^B_:W=N[^YOOVI8X<<A'B$?&6R<V7VX&0C*?]6'S/4)*+9V
MB>8$J28R*22224__T/55XM]??JS^P>L%^.R.G9Y=9CQPQ_-^+^/JT_\`!?\`
M%+VE<M_C(LZ4WZK7LZ@"Y[W-&"UL;_M.II<R?S6>_P!?_NOZJEP3,9BM>+0A
MCRQ$HF^FKYU=]<,VWZGU?5LEVYEFRR_][$;[J<:9W;]_Z)W_`'6K6E_BV^JY
MZIU+]KY;)P>GO_1-/%F0-6_];Q/YS_C_`$_]'8N,(<6D`PZ-#X%>X_4?-Z9E
M_5G#_9E?H4T-]&S'F37:W6]CW?GN<]WK>I_A?5]56,YX('A%<1U+#A]<KD;X
M1H'>2225)M/@OUL_\5/5_P#PT_\`(U>O_4DS]4ND_P#A6O\`ZE>0?6S_`,5/
M5_\`PT_\C5Z_]2?_`!(])_\`"M?Y%:YC^;A_+HP8?GG]'E_\<']$Z7_QUO\`
MU#51_P`4'_*?4_\`B:O^JL5[_'!_1.E_\=;_`-0U4?\`%!_RGU/_`(FK_JK$
MA_N8_P`OTD'^?^CZBJ_4/Z!D_P#%/_ZDJPJ_4/Z!D_\`%/\`^I*K1^8>;-/Y
M9>1>#^K76Z.C8F;<\>I=;Z3:*08W$"S<YSOS6,W*^_ZR?6]H.2[!VT1NUHLV
M@>)=NWJK]1\&O)ZFZ^T!S<2L/8#_`*1YVL=_8:VQ=^KW,Y,<,I_5B<C7$9>7
MRQ<SD<6;)R\:RG%&/$("`W]6LIN']7_K11U<FBUHHRVC<&`RU[>[J7?R?SZT
M'ZS?67+Z-DU4T4UVMMK+R7D@@@[?S5@]>J;T?ZSLR,8>FPNKR&M&@&XEES?Z
MK]K_`//1_K__`$[%_P")=_U24<&,YL9`_5Y8F7"?T2!LJ?-9H\OFB95FP3C`
MS'Z49'23VF1DTXN._(R7BNJH;GO/`"Y*WZX]5S<AU/1L+<!K+FE[X_?>QA;7
M3_;<I_7[,>VO%PFGV/W76#QV0VH?YSG.6[]7^FU=.Z734T#U'M%E[^[GN$NG
M^K]!JAA&&/$,DX\<IGT1/R@1ZMC)/+FYB6''/VX8@#DG'YY2EM&+SS?K=UW`
MN:SJ^$-CN(::W'_BW.+ZK-O[BZO!SL;/Q696*_?58-#W!'TF.'YKVJ/4^GT=
M2PK,2\2UX]KN[7#Z%C?Y3'+DOJ'EV5YV3@//M>SU([!]9%3_`//:[_H(F./+
MBE.,>">.N(#Y91*(SRX,\,629RX\UB$I?/"<?T7_T?4WO8QCGO<&L:"7.)@`
M#ESBO#_KG]9G?6'J[\ACB.GXNZO":>-O^%R2/W\C;_VSZ:]`_P`8V3UV[!;T
M;H^#D9#<L3F9%+"6BJ8^S-?_`*2]W\[_`,!_QJY'ZG_4;J>7UNIW5\&W%P,6
M+K!<W:+7-/Z'';/TF[_?=_P5?I_X16<`C`')(B^@8<O%(B$>NY6ROJ'E8_U+
MKZV6._:`/VG(HUEN(X:,V?Z:EOZS9_UVO\Q5/J-]9O\`F_U@&]\=-S=M>7X-
M/^`R_P#K4[;?^`_XM>UN:US2UP#FN$$'4$'LO&/K']1>L=/ZO?1TW!OR^GO/
MJ8SZF[@UC_\`M._7Z5+O9_Q>Q.QY1D$H9.NH6SQF!C*`VT+[."")&H3KD_\`
M%[E];'3#TOK.'D8]N"`W'ON80+*3_-U[_P#2X_\`-_\`%>DNL564>$D;TS@V
M+?!?K9_XJ>K_`/AI_P"1J]?^I/\`XD>D_P#A6O\`(O,OK-]6_K%D?6/JE^/T
MS)MIMR7NKL962US2!#FG\Y>H_5''OQ?JQTS'R:W4WU8[&V5O$.:X#5KFJSG(
M..%'^5,.($3G?5Y/_'!_1.E_\=;_`-0U4?\`%!_REU/_`(FK_JK%K_XT^E]3
MZCC=.;T_$MRW5VV&P4MW;06M#=R\^/U4^M!_[R,O_ML_WIV,1EAX3(1O^*V?
M$,O$!>C[U(0,_7!R?^*?_P!25X9_S3^L_P#Y49G^8?\`R2E7]4_K.+:R>DY8
M`>TD[#P"/--'+Q!!]P?R_P`),LLB".`[/H?^+ZUC<C,J)][ZZWM'>&E[7_\`
MGQB[9>>X'0^OT^IU#%JLHRL5X+*GM@V,</?Z>[^<_=?5^?\`\8KS_K9]9'M-
M#.G;,@Z;A782#XMJ=_WYZDYC#[N4RQRB=N+7Y6GR7,^S@C#-"<#J8>DRXP3_
M`-)K?6T_;/K+5BU:O:VFD_UGN+_^IL:B?XP/Z=C?\2[_`*I7?JS]7,QN6>K=
M5!%TEU53S+][OI7W?RO]&Q"^NW3NH9>;CNQ,:R]K:G!SJVR`=W"?"<!FQ0$@
M1BB09?H\1&K'EQ9#R^?*8D2SSC*,/THPB?3Q(O\`&!0[U\2\?1?6^OYM(?\`
M]^76]-R69?3\?(K,MLK:[3QCW-_LN0NK]*IZM@OQ+26$PZJP"2QX^@\#_JOY
M"Y+%N^LWU9<['.-]HQB20`'/KG]^FVOWU;_]'8Q0Q`S88P!`R8R:$C7'&79L
MR)Y;F9Y3$RPY@+E$<7MSA^\]Q;;734^ZP[:ZVESW'L&C<XKA_J.U]W6K\D"&
M"I[G?&QX<P?]%/F9WUG^L+1AUX;J,=Q]X`<QKH_TU]VWV?\`!L73]`Z+5T?#
M](.]2^P[[[8B71]%O_!L_,2H8,,XR(.3)0X0;X8_UD6>9YC%.,2,6&Y<<AP\
M<S^C%__2]522224I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE
M*22224__T_54E\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V0`X0DE-!"$`````
M`%,````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2
M`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE-
M!`8```````<`!`````$!`/_A%_EH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED)S\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T
M82\G('@Z>&UP=&L])UA-4"!T;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N
M-B<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA
M9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70])W5U:60Z96,R.&4R9F4M.#,P9"TQ,61C+6(W-#0M93@T9&)A,V5E,S`T
M)PH@('AM;&YS.F5X:68])VAT='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O
M)SX*("`\97AI9CI#;VQO<E-P86-E/C$\+V5X:68Z0V]L;W)3<&%C93X*("`\
M97AI9CI0:7AE;%A$:6UE;G-I;VX^,3<Q/"]E>&EF.E!I>&5L6$1I;65N<VEO
M;CX*("`\97AI9CI0:7AE;%E$:6UE;G-I;VX^-S,\+V5X:68Z4&EX96Q91&EM
M96YS:6]N/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70])W5U:60Z96,R.&4R9F4M.#,P9"TQ,61C+6(W-#0M93@T
M9&)A,V5E,S`T)PH@('AM;&YS.G!D9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M9&8O,2XS+R<^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TG=75I9#IE8S(X93)F92TX,S!D+3$Q9&,M8C<T-"UE
M.#1D8F$S964S,#0G"B`@>&UL;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O
M8F4N8V]M+W!H;W1O<VAO<"\Q+C`O)SX*("`\<&AO=&]S:&]P.DAI<W1O<GD^
M/"]P:&]T;W-H;W`Z2&ES=&]R>3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.F5C,CAE,F9E+3@S,&0M
M,3%D8RUB-S0T+64X-&1B83-E93,P-"<*("!X;6QN<SIT:69F/2=H='1P.B\O
M;G,N861O8F4N8V]M+W1I9F8O,2XP+R<^"B`@/'1I9F8Z3W)I96YT871I;VX^
M,3PO=&EF9CI/<FEE;G1A=&EO;CX*("`\=&EF9CI84F5S;VQU=&EO;CXW,B\Q
M/"]T:69F.EA297-O;'5T:6]N/@H@(#QT:69F.EE297-O;'5T:6]N/C<R+S$\
M+W1I9F8Z65)E<V]L=71I;VX^"B`@/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO
M=&EF9CI297-O;'5T:6]N56YI=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.F5C,CAE,F9E+3@S,&0M
M,3%D8RUB-S0T+64X-&1B83-E93,P-"<*("!X;6QN<SIX87`])VAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\G/@H@(#QX87`Z0W)E871E1&%T93XR,#`W
M+3$P+3(U5#$Q.C(R.C(W+3`U.C`P/"]X87`Z0W)E871E1&%T93X*("`\>&%P
M.DUO9&EF>41A=&4^,C`P-RTQ,"TR-50Q,3HR,CHR-RTP-3HP,#PO>&%P.DUO
M9&EF>41A=&4^"B`@/'AA<#I-971A9&%T841A=&4^,C`P-RTQ,"TR-50Q,3HR
M,CHR-RTP-3HP,#PO>&%P.DUE=&%D871A1&%T93X*("`\>&%P.D-R96%T;W)4
M;V]L/D%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD;W=S/"]X87`Z0W)E871O<E1O
M;VP^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TG=75I9#IE8S(X93)F92TX,S!D+3$Q9&,M8C<T-"UE.#1D8F$S
M964S,#0G"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H
M;W1O<VAO<#IE8S(X93)F9"TX,S!D+3$Q9&,M8C<T-"UE.#1D8F$S964S,#0\
M+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IE8S(X93)F92TX,S!D+3$Q
M9&,M8C<T-"UE.#1D8F$S964S,#0G"B`@>&UL;G,Z9&,])VAT='`Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O)SX*("`\9&,Z9F]R;6%T/FEM86=E+VIP
M96<\+V1C.F9O<FUA=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_X@Q824-#7U!2
M3T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A
M8W-P35-&5`````!)14,@<U)'0@``````````````````]M8``0````#3+4A0
M("``````````````````````````````````````````````````````````
M`````!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B:W!T
M```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0````!1D
M;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#U```
M`"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#```$
M/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H
M="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P``````
M```2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q.38V
M+3(N,0``````````````````````````````````````````````````````
M````````````6%E:(````````/-1``$````!%LQ865H@````````````````
M`````%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``&-I8
M65H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W
M+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````
M``````````````````````````````````````````````````````!D97-C
M`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C
M92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````````````9&5S
M8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q
M.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$``````````````````````````````````'9I
M97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B```````$P)
M5@!0````5Q_G;65A<P`````````!`````````````````````````H\````"
M<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H`"T`
M,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?
M`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!
M&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q
M`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$"
M>@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F
M`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$
MC`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075
M!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'
M80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0
M"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+
M"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF
M#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/
ME@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F
M$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5
M$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;
M&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;
MBANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3
M'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC
M"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8
M)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDK
MG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U
M,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U
M336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT
M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`
M(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>
M1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),
M*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\
M4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9
M:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!7
M8*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-G
MZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X
M;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9W
MLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E
M@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(
MSHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&H
MDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;
M0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'
MI3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O
M%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*
MN<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$
M4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\W
MS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:
M^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6
MYQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS
M&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M
M____[@`.061O8F4`9``````!_]L`A``&!`0$!00&!04&"08%!@D+"`8&"`L,
M"@H+"@H,$`P,#`P,#!`,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0<'
M!PT,#1@0$!@4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!)`*L#`1$``A$!`Q$!_]T`!``6_\0!
MH@````<!`0$!`0``````````!`4#`@8!``<("0H+`0`"`@,!`0$!`0``````
M```!``(#!`4&!P@)"@L0``(!`P,"!`(&!P,$`@8"<P$"`Q$$``4A$C%!4083
M82)Q@10RD:$'%;%"(\%2T>$S%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D
M=,/2X@@F@PD*&!F$E$5&I+16TU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<X2%AH>(B8J+C(V.CX*3E)66EYB9FIN<G9Z?DJ
M.DI::GJ*FJJZRMKJ^A$``@(!`@,%!00%!@0(`P-M`0`"$0,$(1(Q0051$V$B
M!G&!D3*AL?`4P='A(T(54F)R\3,D-$."%I)3):)CLL('<](UXD2#%U23"`D*
M&!DF-D4:)V1T53?RH[/#*"G3X_.$E*2TQ-3D]&5UA96EM<75Y?5&5F9VAI:F
MML;6YO9'5V=WAY>GM\?7Y_<X2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ
M2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#U3BK3ND:,[D*B@LS'H`-R<5?,
M7F3_`)RP\PKKTJZ!IMJ=&@D*1&YYF6=5-.9*E1'S_9%,VN/L\</J.[KIZVCM
MR>]_E[YVL?.GE2SU^SC,(N`4GMV-3%,AXNE>]#T/\N:_-B,)<)<[',2%AD>5
M,W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_P#_T.S_`)V_X[M/
M*;ZSY/U"2UN],K->6J(DGK6]/C(#JWQQ?;V^TO+,C3<!E4AS:<_%PW%\Z:!_
MSD-^8=OK%G/K.J-J6CAP-0LFBB420/\`#)0JJMR"GDN^;.>BA6PW=?#5RO?D
MFFJ_\XT^<;C41<^5IK34?+M]2?3[UYA&RP2_$GJ*022JGJG+ED8ZZ('JVD&4
MM&2;')OS9YYUG\L[>P\@>3]5XS:2'EU[441&$U[<$,T:APW%(1_LOYL&/",M
MSD.?TIRY3B`C%G/_`#C_`.8OS4\XZI<:OK>LRR>7-/!C](Q1(+BX8;)R5`>,
M0/)Z?M<<Q]7CQP%`>HMVFG.>YY/*M1_/K\UHM1NXH_,#K''/*B+Z4&RK(P`^
MQX#,P:/'7)QIZF8*''Y^_FV>GF%S_P`\H/\`FC#^2Q]S#\WD[W'\_?S;'7S"
M_P#R)@_YHQ_)8^Y?S>3O:_Y7]^;7_4PO_P`BH/\`FC'\EC[D_FLC?_*_?S;_
M`.I@D_Y$P?\`-&/Y+'W(_-S[WU=^4FM:GK?Y<:%JNJ3FYU"[MR]Q.0JEF]1A
M6B@+T&:C41$9D#D[7%(F()9=E+8QG\R-5U#2O*%[?:?,8+J(Q\)0`:<I%4[,
M".AS+T.*.3*(RY.N[6SSQ:>4X&I"O]TE_P"4NO:MK?ER:[U2X-S<+<O&KD*M
M%"J0/A`\<M[2P1QY`(BAPM'8FJR9\)E,\4N)FV:]W#L5>;_FUK_FS2[G34T&
M29%E24SB&+U!52O&IXM3J<VO9N'%/B\2MJZO/]MZK48C'P;WOBX8\3-_+EQ=
M7&@:=/=EC=2VT3SEAQ8NR`M4;4-<U^8`3D!RMW.EE*6*)E]1B.),<J;W8J[%
M78J__]'U0RJRE6`96%&4[@@]CBKXK_/3\M3Y*\WNUI&1H6JEKC3F`^&-JUE@
M_P">9-4_XKS>Z3/QQW^H.GU6'AE8Y,J_*_\`/G_#/Y9ZMHUXWJ:KIJT\N*U3
MS$YIP/\`DV[_`+S_`(Q_#E.?2<60$<C]3=AU50(/-Y1Y<T#7/./FFWTNT+3Z
MGJDQ::X?>G(\YIG]E')SF9.8A&^@<2$3DD^Z_*?E?2_+'EZRT+34X6EG&$!_
M:=CN\C>+NU6;.?R3,Y$EW<("(H)>_P"6'Y=N[._EO3F=R69C;QU)8U).W<Y+
MQI]Y8^%'N>,?\Y/^4?*VA^5]'FT?2;73YI;XI));Q)&S+Z+'B2H%149G:#)*
M4C9Z.)K(1$108!_SCGHVDZQ^9`LM5LX;ZT-C._H7""1.2E*-Q:HJ*YDZV9CC
MV/5Q]'$&6[ZE_P"57?ES_P!2UIW_`$C1_P!,U'CS[R[/PH]SXL_,2TM;/S[Y
MBM+6)(+:#4+F.&&,!41%D("J!T`S>X23`$]SILPJ9?7_`.1/_DH_+/\`S"G_
M`).OFEU7]X7;X/H#/,QVYAWYN?\`*!:C\X?^3JYG]F?W\?C]SJ.W?\4G_F_[
MH,/_`"W\X:/Y8\B376HN2\EY*+>WCH9)"$6M`:;#NQS/U^EGFS@1_FNI[(UV
M/3:4RF?XSPQ_BER5D_/^W,Y#:._H5V(F7G3Y<:9$]BGI+[&8]J(W]!KWL^\J
M^<]#\S6K3:=*?4BIZ]M(.,J5Z5'<?Y2YJ]3I9X34G>Z+7XM3&X'WQ_B0GG/S
M_IOE1[5;VWFG^MARAAX[>G2M>1'\V3TNCEFOA(]+5VAVG#2UQ`GC_FI_IM\E
M_I]M>HI1+F))D5NH$BA@#3OOF-.)C(@_PN=BR"<!(?Q#B8AYJ_-SRYH5R]G$
M'U"]C/&6.$@(A\&D.U?9>69^F[,R9!?TQ=5K>W,."7#]<_Z+';;\_K4R@76D
M2)$3]J.568#_`%2JU^_,J78LJVDZ^'M/&_5`@>]Z-Y=\S:-YAL?KFESB:,'C
M(A'%T;KQ=3N#FJSX)XI5(/0:75X\\>*!L)IE+DO_TO5.*L._-OR;I/FOR/J%
MCJ$B6QMXVNK6^DH!!+"I8.3V3]F3_(R[3Y#"8(:LT!*)!?"GW'W'3Z,Z%T1#
MZC_YQ1\N:!'Y<OO,,4J7&MW$S6MRM/BMHDW6/?\`W[_>,W[7P_R9J.T)RXA'
M^%VNC@!&^KWG->YKL5>$?\Y<_P#*(Z'_`-M$_P#)E\V'9WU'W.%KOI#S;_G%
MW_R:B_\`;/N?UIF5K_[OXN-HOK?8&:5VSX)_,_\`\F/YG_[:=U_R=.=#@^@>
MYT6?ZS[WUU^1/_DH_+/_`#"G_DZ^:;5?WA=O@^@,\S';F'?FY_R@6H_.'_DZ
MN9_9G]_'X_<ZCMW_`!2?^;_N@\V_*'R;9:]?W%[J<?KV-AQ6.W8_`\K[_$.X
M516F;;M35RQ@1C]4GG>P.SXYI&<_5#'_``_TGLUWY6\N7=JUK/IELT##CQ$2
M+0>Q`!'T9H(ZC)$V)&WL)Z/%*/"8QKW/#9HIO(/YD*EM(QM8Y4(J=WM9^JMX
M\?\`B2YT8D-5IM^?^_B\48G0:VHGTW_TKFR/\_2#)HI!J"DY!_X#,/L3^/\`
MS?TNP]J/\G_G?[U/_-'F2?0ORNT^2U?T[R[M;:V@<=5YQ`LP]U4;9C:;3C+J
M2#],92D[#6ZLX-#$CZI0A&/^E2'\GO(>GWMHWF#585N>3LEE#*.2?":-(P/V
MB6V6N9/:FMD)>'$U_.<#L'LR,X^-D'%?T<7^Z>G:IY7\OZI9O:7EA#)$PH*(
MJLONK`54CVS48]1.!L$V])FT>+)'AE$4\1TZ2]_+_P#,7ZGZI:S,BQ2UV$EM
M,?@9A_,E:_ZRYT62M5I[_B_W[QF$RT&LX+]!/^PD^@>2^/:OT>.<N]X__]/U
M3BKYT_YR@_,_B@\BZ5+\4@677)$/1/M1V^W\WVY/\GCFST&#^,_YK@:S-0X0
M\/T3R+YAUKRUK/F*QAYZ=H80W1WY-R/Q"/Q])?WDG^3FPEEC&0B><G"AA,HD
M]R>?DS^9$OD;S=%=3,3HM_QM]5C&X$9/PS`?S0DU_P!3GE6JP>)'^DSTN7@E
MY/MV&:*:))HG$D4BAXW4U#*PJ"#X$9H7<KL5>$?\Y<_\HCH?_;1/_)E\V'9W
MU'W.%KOI#S;_`)Q=_P#)J+_VS[G]:9E:_P#N_BXVB^M]@9I7;/@G\S__`"8_
MF?\`[:=U_P`G3G0X/H'N=%G^L^]]=?D3_P"2C\L_\PI_Y.OFFU7]X7;X/H#/
M,QVYAWYN?\H%J/SA_P"3JYG]F?W\?C]SJ.W?\4G_`)O^Z"2_D.J#RS?$'XC>
M'E]$:4S([8_O!_5</V9`\"7]?_>AZ7FH>C>"?G45?SO"B']Y]6A4TZU+M3.D
M[(VPGWO#^T.^I`_HA-/SU4JF@*>HAE!^8$>4]C<Y_#]+D>TW+'_G?[UK\TED
M/D+RF1_=B.,-\S;K3^.'L[^_R?C^)>VQ_@F'X?[AGOY6/$_D+2?3(/&-E:G\
MPD:N:WM$$9Y.]['(_*PKN_2RO,)V;P3\Z2C>>HE3[8MX`U/$L:?AG3=D[83[
MR\-[0[ZD`<^&+VOA)[_[R<?]EG/6/]D]CPG_`&#_`/_4[U^:GY@6?D;RE<ZM
M)Q>^D_<:;;$[R7#`\=OY$^V_^3EV#"<DJ:LN00C;XCABUOS+Y@6-2]]K6KW-
M.1W:2:9MR?;?_8KF^VA'RBZ;><GW-Y$\C:7Y4\FVOEN)%EB2(B]=A7UY91^^
M=AWYG;_4^'-!ERF<C)W>.`C&GQ]^;_Y?R^2/.EUIJ*?T7<UN=*D/0P.?[NOC
M$WP?\#FZTV;Q(WU=1J<7!)[7_P`XQ?F<=1TYO)>J2UO=/0R:5(YWDMA]J*O=
MH?V?^*_]3,'7X*/&.OU.;H\W$*+WO-<YKPC_`)RY_P"41T/_`+:)_P"3+YL.
MSOJ/N<+7?2'FW_.+O_DU%_[9]S^M,RM?_=_%QM%];[`S2NV?!7YG_P#DQ_,_
M_;3NO^3ISH<'T#W.BS_6?>RKRK_SD1YW\L^7K'0;"UL7L["/TH7E20N1R+?$
M0X'?PRK)HX2D26Z&KE$4FW_0UGYC?\L>G?\`(N7_`)KR'Y"'FR_/262_\Y`^
M=/-@&@:E;64=G>']Z\*.)!Z?QBA9V'5?#,C2:.$,@(MUW:VJE+32!\O]TSC\
MKO.\?EBYD@U-772-0/)9PI(26/X2VWVE_9>GV<N[1TGC"X_7!U/8G:(TQK)_
M=Y/XOZ3U>]_,_P`D6UHUR-4BGH*K##5Y&/@%I_Q+-)#L_-(UPT]5D[7TT8\7
M&#_5>5^7;6_\^_F&VJS1%+**5)[CNJ114]**O\S4_P")9NM1*.FT_`/J^G_B
MI/,:2$M=J_$(]$3Q?Z7Z8IW^?_\`?:-_JS_\:9C=B?Q_YOZ7+]J?\G_G?[UE
M&L>6'\Q_EG8V,-/K<=I;3VA/0R)$/A_V8JN86+4>%J3+IQ2XG:ZC1_F-'&`^
MK@C*'];A81^6'Y@0^6VGT+7@]O:B0F.1E),$IV='4;A2=_\`6S9]H:$Y:R8]
MS_NG2=C=IC3$X<WI%_Z63T75/S2\E6-FTZ:C'=R`5CM[<\W<]AX+\VS4X^SL
MTS7#P_UGH,W;&FA&^(2_HQ>7>4],U3SWYZ?6KR,BRBF$]T_["A/[J!2>IV'_
M`!+-SJ<D=-@X(_41P_\`%3>9T.&>NU7BR'H!XO\`B8/?=\YA[I__U>^^=/RN
M\G^<[FVN/,-M+=-:(R6Z+/+&BAC5CQ1E7D?YLNQ9Y0^EKGBC+F@O*WY*_EUY
M7UF/6=(TTQ:A"K)%+)+)+QYBC$*[$<J;<L.34SF*)1#!&)L,YRAM8YYT_+SR
MGYSM[:#S#9_6EM',ENRN\;J6%&')"#1NXRW%FE#Z2PGCC+FQ_1OR$_+31M5M
M=5TVPFM[^RD$MO,MS-56'L6H01LRG[662U<Y"B6$=/`&P]#S&;F/>=/(/ECS
MG96]GY@MFN;>UE]:%5D>.C\2M:H178Y9BRR@;BPGC$A12ORE^3GD'REK'Z7T
M.Q>WOO2:'U&FED'!Z%AQ=B.V3R:B<Q1+&&&,389KE#:\[U;\@/ROU75+O4[W
M39)+R]E>>X<7$RAI)#R8T#4&^9,=7D`H%HEIX$W2$_Z%M_*/_JU2?]),_P#S
M5A_.Y.]'Y6'<[_H6W\H_^K5)_P!),_\`S5C^=R=Z_E8=RO9?\X\_E79W*7-O
MIDBS1UXM]8F/44Z%LE'7Y0;!:\N@Q9(F,AL62?\`*NO*1T3]"M9<K%9&EC#,
MQ='?JR.3R7(_G<O'QWZFO^2\'A>%P^A(8OR.\G)/ZC274D=:^D9`!\B0H;,H
M]KYJ_A<`>SFF!OU?-FND:+I>CV:V>FVZ6ULN_!!U/<L3NS>YS7Y<LLAN1XB[
MG!@ABCPP'#%`^8_)F@>8F@;5H&F-L&$5'9*<Z<OLD>&68-5/%?":MIU>@Q:B
MO$'%PIK96<%G:0VD`XPP(L42DDT5!Q45/L,HE(DDGF7*A`1B(CE'9(O,GY?^
M5_,+^M?VO&ZI3ZU"?3E('B1LW^R&9.#6Y,7TG;^:X.K[,P9]YQ]7\X?4D-M^
M2'DV*0/*UU.`:^F\@"GY\54_CF5+M?,>5!P8>SNF!L\4OBSC3=,T_3+1+.PM
MTMK:/[,48H/G[GWS73R2F;D;+NL6*../#$<,43D&Q__6]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__7]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__0]4XJ[%78J[%78J[%
A78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
